NICE has published draft guidance stating that although Translarna (also known as ataluren) is clinically effective and an innovative treatment, there is doubt as to its cost effectiveness. NICE’s draft recommendation is that people currently receiving Translarna should continue to have access to it until they and their NHS clinician consider it appropriate to stop,…
Breakthrough in identifying common neural processes in Parkinson’s disease
New research could lead to treatments that halt the advance of Parkinson’s disease. Study from University of Haifa could have significant implications for how Parkinson’s disease is treated following a breakthrough in identifying common neural processes for the first time. A new study conducted by University of Haifa has identified processes that may help prevent…
AJOVY®▼ (fremanezumab) for treatment of migraine in patients with co-morbid depression
Two separate analyses1,2 presented at the Migraine Trust International Symposium (MTIS) demonstrate the effectiveness of AJOVY▼(fremanezumab) for the treatment of migraine in patients with migraine and co-morbid depression Depression and anxiety are common co-morbidities experienced by around half of all patients with migraine3,4 and are associated with more pain, disability and a reduced quality of…
Blood type may be linked to risk of early stroke
Gene variants associated with a person’s blood type may be linked to their risk of early stroke, according to a new meta-analysis published in the August 31, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. The meta-analysis included all available data from genetic studies that included young adult ischaemic stroke, which…
WFNR Franz Gerstenbrand Award 2022
This year’s WFNR Franz Gerstenbrand Award closes for entries on 31st October, with £3,000 for the winner. The Award is open to clinicians, researchers or allied health professionals worldwide currently working in neurorehabilitation. Entries are open to WFNR members and non-members and are particularly encouraged from those individuals under the age of 35 years. …
New method of examining the brain’s electrical signals
Method could hold the key to better treatment of epilepsy and schizophrenia Researchers are exploring new ways to ‘listen’ to and record electrical signals emitted from brain cells Findings could be used to help treat conditions like epilepsy and schizophrenia Project will use newly developed nanomaterials to keep removed samples of brain healthy for longer…
Imaging yields new insights into stroke
Synchrotron’s “superhuman vision” made it easy to detect markers of brain damage Haemorrhagic stroke, where a weakened vessel in the brain ruptures, can lead to permanent disability or death. Across the globe, over 15 million people are coping with its effects. A study by researchers from the University of Saskatchewan (USask) and Curtin University in…
International Encephalitis Research Seed Funding 2022
Deadline: 9th September 2022 The Encephalitis Society are inviting researchers to apply for up to £10,000 in seed funding for a project specific on encephalitis with a duration of up to 18 months. The fund is open to applicants from low-to-middle income countries worldwide and to all levels from medical students, junior doctors and early…
First ever Marketing Authorisation Application (MAA) for biosimilar natalizumab
Polpharma Biologics announced on July 15th 2022 that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorisation Application (MAA) for biosimilar natalizumab, a proposed biosimilar to Tysabri®. In the European Union, Tysabri is approved to treat adults with relapsing-remitting MS (RRMS) who have highly active disease. It is approved for adults with relapsing…
